Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity

Related Experiment Video

Updated: May 10, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Martin Lorenz1, Andreas Evers, Michael Wagner

  • 1Diabetes Division/Res. & Transl. Med, Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, 65926 Frankfurt am Main, Germany. Martin.Lorenz@sanofi.com

Bioorganic & Medicinal Chemistry Letters
|June 8, 2013
PubMed

Insights

The rise in type 2 diabetes and obesity necessitates new treatments. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer improved glycemic control and modest weight reduction, with newer agents showing greater potential.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes and obesity are global epidemics linked to increased mortality and morbidity.
  • Current anti-diabetic therapies often lack significant weight reduction benefits.
  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only approved agents providing modest weight loss alongside glycemic control.

Purpose of the Study:

  • To address the clinical need for anti-diabetic therapies that also promote weight reduction.
  • To explore the therapeutic potential of GLP-1 receptor agonists (GLP-1 RAs) and next-generation co-agonists.
  • To review advancements in optimizing GLP-1 RA administration for improved patient outcomes.

Main Methods:

  • Review of current clinical evaluations for optimized GLP-1 RA administration (once-weekly to once-monthly).
  • Analysis of the physiological effects of glucagon-like peptide-1 (GLP-1) on glycemic control, appetite, and food intake.
  • Examination of next-generation peptidic co-agonists combining GLP-1 with other gastro-intestinal hormones.

Main Results:

  • GLP-1 RAs demonstrate efficacy in improving glycemic control and reducing appetite.
  • Ongoing research focuses on extending the dosing interval of GLP-1 RAs.
  • Next-generation co-agonists aim to enhance therapeutic benefits beyond GLP-1 RAs alone.

Conclusions:

  • GLP-1 RAs represent a key therapeutic class for managing type 2 diabetes and obesity.
  • Optimizing administration frequency and exploring co-agonists are crucial for future anti-diabetic and weight-management strategies.
  • Further development of advanced peptidic agonists holds promise for greater therapeutic impact.

More Related Videos

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine07:00

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine

Published on: February 26, 2019

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate05:58

Measuring Relative Insulin Secretion using a Co-Secreted Luciferase Surrogate

Published on: June 25, 2019

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...